Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany

E. Smits; F. Andreotti; E. Houben; H.J.G.M. Crijns; S. Haas; G. Spentzouris; T. Schink; R. Gini; C. Bartolini; F. Penning-van Beest; R. Herings

doi:10.1007/s40801-021-00289-w

Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany

E. Smits^*, F. Andreotti, E. Houben, H.J.G.M. Crijns, S. Haas, G. Spentzouris, T. Schink, R. Gini, C. Bartolini, F. Penning-van Beest, R. Herings

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	199-209
Number of pages	11
Journal	Drugs-Real World Outcomes
Volume	9
Issue number	2
Early online date	6 Jan 2022
DOIs	https://doi.org/10.1007/s40801-021-00289-w
Publication status	Published - Jun 2022

Keywords

DOSING FREQUENCY
MEDICATION ADHERENCE
STROKE RISK
WARFARIN
SAFETY
EFFICACY
RIVAROXABAN
DABIGATRAN
REGIMENS
THERAPY

Access to Document

10.1007/s40801-021-00289-wLicence: CC BY-NC

Cite this

Smits, E., Andreotti, F., Houben, E., Crijns, H. J. G. M., Haas, S., Spentzouris, G., Schink, T., Gini, R., Bartolini, C., Penning-van Beest, F., & Herings, R. (2022). Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs-Real World Outcomes, 9(2), 199-209. https://doi.org/10.1007/s40801-021-00289-w

Smits, E. ; Andreotti, F. ; Houben, E. ; Crijns, H.J.G.M. ; Haas, S. ; Spentzouris, G. ; Schink, T. ; Gini, R. ; Bartolini, C. ; Penning-van Beest, F. ; Herings, R. / Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. In: Drugs-Real World Outcomes. 2022 ; Vol. 9, No. 2. pp. 199-209.

@article{d77465c8f7a245649aa1e4d6ffd3d6c5,

title = "Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany",

keywords = "DOSING FREQUENCY, MEDICATION ADHERENCE, STROKE RISK, WARFARIN, SAFETY, EFFICACY, RIVAROXABAN, DABIGATRAN, REGIMENS, THERAPY",

author = "E. Smits and F. Andreotti and E. Houben and H.J.G.M. Crijns and S. Haas and G. Spentzouris and T. Schink and R. Gini and C. Bartolini and {Penning-van Beest}, F. and R. Herings",

year = "2022",

month = jun,

doi = "10.1007/s40801-021-00289-w",

language = "English",

volume = "9",

pages = "199--209",

journal = "Drugs-Real World Outcomes",

issn = "2199-1154",

publisher = "Adis International Ltd",

number = "2",

}

Smits, E, Andreotti, F, Houben, E, Crijns, HJGM, Haas, S, Spentzouris, G, Schink, T, Gini, R, Bartolini, C, Penning-van Beest, F & Herings, R 2022, 'Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany', Drugs-Real World Outcomes, vol. 9, no. 2, pp. 199-209. https://doi.org/10.1007/s40801-021-00289-w

Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. / Smits, E.; Andreotti, F.; Houben, E.; Crijns, H.J.G.M.; Haas, S.; Spentzouris, G.; Schink, T.; Gini, R.; Bartolini, C.; Penning-van Beest, F.; Herings, R.

In: Drugs-Real World Outcomes, Vol. 9, No. 2, 06.2022, p. 199-209.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany

AU - Smits, E.

AU - Andreotti, F.

AU - Houben, E.

AU - Crijns, H.J.G.M.

AU - Haas, S.

AU - Spentzouris, G.

AU - Schink, T.

AU - Gini, R.

AU - Bartolini, C.

AU - Penning-van Beest, F.

AU - Herings, R.

PY - 2022/6

Y1 - 2022/6

KW - DOSING FREQUENCY

KW - MEDICATION ADHERENCE

KW - STROKE RISK

KW - WARFARIN

KW - SAFETY

KW - EFFICACY

KW - RIVAROXABAN

KW - DABIGATRAN

KW - REGIMENS

KW - THERAPY

U2 - 10.1007/s40801-021-00289-w

DO - 10.1007/s40801-021-00289-w

M3 - Article

C2 - 34993898

VL - 9

SP - 199

EP - 209

JO - Drugs-Real World Outcomes

JF - Drugs-Real World Outcomes

SN - 2199-1154

IS - 2

ER -